================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULES 13d-1(b), (c) AND (d) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
___________
ACADIA PHARMACEUTICALS INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock 004225108
- ------------------------------------- -----------------------------------------
(Title of class of securities) (CUSIP number)
April 20, 2005
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[-} Rule 13d-1(d)
__________
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
Continued on Following Pages
Page 1 of 6
================================================================================
- ------------------------------------ -------------------------------------------- ---------------------------------------
CUSIP No. 004225108 13G Page 2 of 6
- ------------------------------------ -------------------------------------------- ---------------------------------------
- ----------------------------- --------------------------------------------------- --------------------------------------------------
1 NAME OF REPORTING PERSONS: Nomura International plc on behalf of
Nomura Phase4 Ventures LP, Nomura Phase4 GP
Limited and Nomura Phase4 Ventures Limited
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY): Not Applicable
- ----------------------------- ---------------------------------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:*
(a) [ ]
(b) [X]
- ----------------------------- ------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ----------------------------- --------------------------------------------------- --------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION: England and Wales
- ------------------------------------ ------ ------------------------------------------------ ---------------------------------------
NUMBER OF 5 SOLE VOTING POWER: 2,199,010
SHARES
------ ------------------------------------------------ ---------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER: 0
OWNED BY
------ ------------------------------------------------ ---------------------------------------
EACH 7 SOLE DISPOSITIVE POWER: 2,199,010
REPORTING
------ ------------------------------------------------ ---------------------------------------
PERSON WITH 8 SHARED DISPOSITIVE POWER: 0
- ----------------------------- -------------------------------------------------------------- ---------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 2,199,010
- ----------------------------- ---------------------------------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:*
[ ]
- ----------------------------- ---------------------------------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 9.43%
- ----------------------------- --------------------------------------------------- --------------------------------------------------
12 TYPE OF REPORTING PERSON: CO, OO
- ----------------------------- --------------------------------------------------- --------------------------------------------------
2
ITEM 1. NAME OF ISSUER AND ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
(a) Name of Issuer: ACADIA Pharmaceuticals Inc. (the "Issuer")
(b) Address of Issuer's Principal Executive Offices:
311 Sorrento Valley Boulevard
San Diego, CA 92121
ITEM 2. NAME OF PERSON FILING
(a) Name of Persons Filing:
See Item 1 on the cover page. See also Schedule I.
(b) Address of Principal Business Office or, if None, Residence:
Nomura House
1 St Martins-le-Grand
London, EC1A 4NP
United Kingdom
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b)
OR (c), CHECK WHETHER THE PERSON FILING IS:
Not applicable.
ITEM 4. OWNERSHIP
The percentage ownership of the reporting persons is based on
23,328,818 shares comprised of (a) 18,051,197 shares of Common Stock outstanding
as of March 14, 2005, as reported by the Issuer in its Form 10-K for the period
ending December 31, 2004 and (b) 5,277,621 shares of Common Stock issued
pursuant to the Securities Purchase Agreement dated April 15, 2005. See also
Schedule I.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable.
3
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
See Schedule I.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION
(a) Not applicable.
(b) By signing below, the undersigned certifies that, to the best
of his or its knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction
having that purpose or effect.
[The remainder of this page intentionally left blank.]
4
SIGNATURE
After reasonable inquiry and to the best of our knowledge and
belief, the undersigned certify that the information set forth in this statement
is true, complete and correct.
Date: April 25, 2005
NOMURA INTERNATIONAL PLC
By: /s/ Terence Kyle
-------------------------------------------
Name: Terence Kyle
Title: General Counsel
as attorney for Nomura International plc
under a power of attorney dated May 4, 2004
5
SCHEDULE I
This statement is being filed by Nomura International plc ("NI"), a public
limited company incorporated under the laws of England and Wales, on behalf of
itself and Nomura Phase4 Ventures LP ("NLP"), Nomura Phase4 GP Limited ("NGP")
and Nomura Phase4 Ventures Limited ("NVL") (collectively, the "Reporting
Entities"). Each of the Reporting Entities has the address of Nomura House, 1 St
Martins-le-Grand, London, EC1A 4NP, United Kingdom. NI owns directly all of the
stock of NVL. NVL owns directly all of the stock of NGP. NGP is the manager of
NLP.
NLP acquired 2,199,010 shares of Common Stock of the Issuer pursuant to that
certain Securities Purchase Agreement dated April 15, 2005 by and among the
Issuer and certain purchasers listed therein.
NI, NGP and NVL each disclaim beneficial ownership of the securities held
directly by NLP.
6